Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis Moreá>
"INO has extraordinary potential; I really want to see CEO Joseph Kim and Dave Weiner push this technology into the future." (10/24/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Patrick Cox Moreá>
"CPRX is an emerging biotechnology company in the white hot space of orphan drug medicines." (11/7/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Scott Henry Moreá>
"BDSI's buprenorphine product for chronic pain could be a $500M+/year revenue-generating drug if approved." (11/7/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Scott Henry Moreá>
Companies Commented On
- Abbott Laboratories
- Amgen Inc.
- BG Medicine
- Cardinal Health Inc.
- Covidien Ltd.
- Exact Sciences Corp.
- Genetic Sciences
- Genetic Technologies Ltd.
- Genomic Health Inc.
- Johnson & Johnson
- Laboratory Corporation of America Holdings
- Mesoblast Ltd.
- Myriad Genetics Inc.
- Navidea Biopharmaceuticals Inc.
- NeoGenomics Laboratories
- OPKO Health Inc.
- Pfizer Inc.
- Quest Diagnostics
- Response Genetics
- Sequenom Inc.
- Vermillion, Inc.
Kevin DeGeeter is a director at Ladenburg Thalmann & Co. Inc. He is responsible for equity research coverage of personalized medicine and medical device companies with market capitalizations between $50 million and $5 billion. His coverage focuses on molecular diagnostics and medical equipment used in oncology, cardiovascular disease and infectious disease, as well as related research markets. Prior to joining Ladenburg Thalmann he was an analyst at Oppenheimer & Co., with responsibility for small-cap molecular diagnostic and biotechnology stocks. He has 10 years of buyside and sellside research experience, including positions with J. P. Morgan, PaineWebber, Natexis Bleichroeder and Manning & Napier Advisors. DeGeeter received a bachelor's degree in economics from Colgate University.
Diagnostics and Stem Cells Power Productive Portfolios: Kevin DeGeeter (5/30/13) New medical tests can be moneymakers for small- and mid-cap companies: They save insurers the pain of paying more to treat maladies and save patients from unnecessary treatments. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Director Kevin DeGeeter of Ladenburg, Thalmann & Co. makes his case for diagnostics companies with compelling ideas in the realms of cancer, cardiovascular and surgical testing. He also has one interesting stem cell idea to share.
Testing, Testing: Analyst Kevin DeGeeter on Five Good Bets in Cancer Diagnostics (11/29/12) Because margins in diagnostics and life sciences tools tend to decline over time, the industry is all about scale. The goal is either to develop novel products or tests with high profit potential, or to acquire them. Another strategy is to develop economies of scale through consolidation. In this interview with The Life Sciences Report, Kevin DeGeeter, senior analyst and director of healthcare research for Ladenburg Thalmann, has singled out five important companies with exciting business models or products.
"GENE launched a pretty interesting test for predicting a woman's nonhereditary risk of breast cancer." (5/10/12) Genetic Technologies Ltd. - The Life Sciences Report Interview with Kevin DeGeeter Moreá>
"Rapid changes in underlying technology have created a pressing need for a company like NGNM to help bridge the gap. (5/10/12) NeoGenomics Laboratories - The Life Sciences Report Interview with Kevin DeGeeter Moreá>
"CPRX has a few programs in indications that are less crowded and do not have many successful treatment options." (11/26/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Michael Hay Moreá>
"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay Moreá>
"We expect FDA approval in the near termŚlikely by the end of the yearŚfor OCLS' Microcyn Hydrogel device." (11/26/13) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Jocelyn August Moreá>